Navidea Biopharmaceuticals to Announce Fourth Quarter and Year-End 2014 Financial Results on March 5, 2015
February 26 2015 - 7:30AM
Business Wire
- Conference call with investment community
to follow at 8:30 a.m. EST -
Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), today
announced that the Company will report its financial results for
the fourth quarter and year-end 2014, on Thursday, March 5, 2015
prior to a conference call with the investment community, scheduled
at 8:30 a.m. EST.
Investors and the public are invited to access the live audio
webcast through the link below. Participants who would like to ask
questions during the question and answer session must participate
by telephone also. Participants are encouraged to log-in and/or
dial-in fifteen minutes before the conference call begins. The
webcast replay is expected to be available on our investor website,
http://ir.navidea.com, approximately two to four hours after the
live event.
Event: Navidea Biopharmaceuticals Q4 and Year-End 2014
Financial Results Conference Call Date/Time: Thursday, March 5,
2015 at 8:30 a.m. EST Webcast Link:
http://edge.media-server.com/m/p/wnxb6jnn/lan/en
Dial-in Number – US: 1-(800) 708-4540 Dial in Number – Int’l: 1
(847) 619-6397 Participant Passcode: 39040655 Replay
A webcast replay will be available on the
Investor Relations section of our website at http://ir.navidea.com
for 30 days.
About Navidea Biopharmaceuticals Inc.
Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB) is a
commercial stage precision medicine company focused on the
development and commercialization of precision diagnostics,
therapeutics and radiopharmaceutical agents. Navidea is developing
multiple precision-targeted products and platforms including
Manocept™, NAV4694, and NAV5001, to help identify the sites and
pathways of undetected disease and enable better diagnostic
accuracy, clinical decision-making, targeted treatment and,
ultimately, patient care. Lymphoseek® (technetium Tc 99m
tilmanocept) injection, Navidea’s first commercial product from the
Manocept platform, was approved by the FDA in March 2013 and by the
EMA in November 2014. Navidea’s strategy is to deliver superior
growth and shareholder return by bringing to market novel
radiopharmaceutical agents and therapeutics, and advancing the
Company’s pipeline through global partnering and commercialization
efforts. For more information, please visit www.navidea.com.
Navidea BiopharmaceuticalsBrent Larson, 614-822-2330Executive VP
& CFOorSharon Correia, 978-655-2686Associate Director,
Corporate Communications
Navidea Biopharmaceuticals (AMEX:NAVB)
Historical Stock Chart
From Aug 2024 to Sep 2024
Navidea Biopharmaceuticals (AMEX:NAVB)
Historical Stock Chart
From Sep 2023 to Sep 2024